儿童过敏性哮喘的过敏原特异性免疫治疗:系统综述
该系统综述评估皮下免疫治疗(SCIT)和舌下免疫治疗(SLIT)在儿童过敏性哮喘中的疗效与安全性。中等强度证据表明SCIT可减少长期哮喘药物使用;低强度证据提示SCIT和SLIT可能改善生活质量或FEV1,但哮喘症状和医疗使用证据不足。局部和全身过敏反应常见,但过敏性休克罕见报道。
要点
- SCIT有中等强度证据减少儿童过敏性哮喘的长期药物使用。
- SCIT和SLIT对生活质量和FEV1的改善证据强度低。
- 局部和全身过敏反应常见,但过敏性休克罕见报道。
核心结论
- 在过敏性哮喘儿童中,SCIT可能减少长期哮喘药物使用。
- 局部和全身过敏反应常见,但过敏性休克罕见报道。
研究设计与样本
- 系统综述检索PubMed、Embase、Cochrane对照试验中心注册库(2005年1月1日至2017年5月8日)、ClinicalTrials.gov及美国FDA不良事件报告系统。
- 纳入40项研究:17项SCIT试验、11项SLIT试验、8项SCIT安全性非随机对照试验和4项SLIT安全性非随机对照试验。
- 疗效仅纳入随机对照试验,安全性纳入随机和非随机对照试验,研究对象为≤18岁儿童。
主要发现
- 中等强度证据表明SCIT减少长期哮喘药物使用。
- 低强度证据表明SCIT改善哮喘相关生活质量和第一秒用力呼气容积(FEV1)。
- 低强度证据表明SLIT改善药物使用和FEV1。
- 哮喘症状和医疗使用方面的证据不足。
关键数值与推荐
- SCIT减少长期哮喘药物使用为中等强度证据。
- SCIT改善生活质量和FEV1为低强度证据。
- SLIT改善药物使用和FEV1为低强度证据。
临床怎么用
- 对于过敏性哮喘儿童,可考虑SCIT以减少长期哮喘药物使用。
- 使用SCIT或SLIT时需监测局部和全身过敏反应,过敏性休克虽罕见但仍需警惕。
局限性
- 无试验使用验证工具评估哮喘症状。
- 研究特征和结局报告异质性大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Treatment options for allergic asthma include allergen avoidance, pharmacotherapy, and allergen immunotherapy. OBJECTIVES: Summarize and update current evidence for the efficacy and safety of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) in pediatric allergic asthma. DATA SOURCES: PubMed, Embase, Cochrane Central Register of Controlled Trials (January 1, 2005, through May 8, 2017), ClinicalTrials.gov, and the US Food and Drug Administration Adverse Event Reporting System. We reevaluated trials from our 2013 systematic review. STUDY SELECTION: We included studies with children ≤18 years of age in which researchers reported on prespecified outcomes and had an intervention arm receiving aeroallergen SCIT or SLIT. Only randomized controlled trials (RCTs) were included for efficacy. RCTs and non-RCTs were included for safety outcomes. DATA EXTRACTION: Two reviewers extracted data. We included 40 studies (17 SCIT trials, 11 SLIT trials, 8 non-RCTs for SCIT safety, and 4 non-RCTs for SLIT safety). RESULTS: We found moderate-strength evidence that SCIT reduces long-term asthma medication use. We found low-strength evidence that SCIT improves asthma-related quality of life and forced expiratory volume in 1 second. There was also low-strength evidence that SLIT improves medication use and forced expiratory volume in 1 second. There was insufficient evidence on asthma symptoms and health care use. LIMITATIONS: There were no trials in which researchers evaluated asthma symptoms using a validated tool. Study characteristics and outcomes were reported heterogeneously. CONCLUSIONS: In children with allergic asthma, SCIT may reduce long-term asthma medication use. Local and systemic allergic reactions are common, but anaphylaxis is reported rarely.
引用
- Rice JL, Diette GB, Suarez-Cuervo C, et al. Allergen-Specific Immunotherapy in the Treatment of Pediatric Asthma: A Systematic Review. Pediatrics. 2018. PMID: 29572287. doi:10.1542/peds.2017-3833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。